Product Description
Mechanisms of Action: c-MET Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Spain
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-514268-18-00 |
I4C-MC-JTBB | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |
12% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|
